Investors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised €125m – a quarter more than initially anticipated.
Irish drug developer Icon plc has announced that, come March 2017, Steve Cutler will take over the leadership of the company. He succeeds Ciaran Murray, who will in turn transition to the role of Chairman of the Board.
https://european-biotechnology.com/wp-content/uploads/2024/04/steve-cutler.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-27 15:58:372016-10-27 15:58:37Icon plc: Rising through the ranks
Part microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological production of molecules. The bacteria have been engineered to respond to light signals.
Nordic Nanovector is expanding its foothold in cancer-fighting ADCs. The Oslo-based biotech has inked a leukaemia pact with Wilex subsidiary Heidelberg Pharma.
https://european-biotechnology.com/wp-content/uploads/2024/04/20161026-leukaemias.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-10-26 09:47:362016-10-26 09:47:36Nordic Nanovector in blood cancer pact
Miquel A. Pericàs has taken over as general director of the Barcelona Institute of Science and Technology (BIST). The chemical engineer has been holding the position of director of the Institute of Chemical Research of Catalonia since 2000.
https://european-biotechnology.com/wp-content/uploads/2024/04/miquel-pericas.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-25 09:50:492016-10-25 09:50:49BIST: Distinguished director
Trial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now.
3P Biopharmaceuticals has hired Andrew Carver as its new Senior Head of Business Development. Carver joins 3P from UK-based CDMO Fujifilm Diosynth Biotechnology.
After being leaderless for over a year, EffRx has a new CEO. In October, EffRx announced that Lorenzo Bosisio has taken over the company’s helm in July.
New name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-10-20 11:21:042016-10-20 11:21:04Dilaforette: Going public with a new name
Belgian Fund+ raises €125m for biotechs
Latest NewsInvestors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised €125m – a quarter more than initially anticipated.
Icon plc: Rising through the ranks
AppointmentsETH builds cyborg bacteria
Latest NewsPart microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological production of molecules. The bacteria have been engineered to respond to light signals.
Nordic Nanovector in blood cancer pact
Latest NewsThermo Scientific DreamTaq DNA Polymerase
ProductsThe enhanced Taq DNA polymerase, available in standard and hot-start formats, offers a balance between performance and value.
BIST: Distinguished director
AppointmentsEMA unveils trial data
Latest News3P Biopharmaceuticals: Business Developer
AppointmentsEffRx Pharmaceuticals: Filling a vacancy
AppointmentsDilaforette: Going public with a new name
Latest NewsNew name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.